Anti-spasmogenic activity of isoenzyme-selective phosphodiesterase inhibitors in guinea-pig trachealis

British Journal of Pharmacology

Volumn 128, Issue 2, 1999, Pages 327-336

  Bernareggi, Micacla M ^a   Belvisi, Maria G ^a,b   Patel, Hema ^a   Barnes, Peter J ^a   Giembycz, Mark A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Discovery Biology   (United Kingdom)

Author keywords

Asthma treatment with phosphodiesterase inhibitors; Guinea pig trachealis; Phosphodiesterase inhibitors anti spasmogenic activity; Rolipram; SK and F 94120 anti spasmogenic activity; Zaprinast; Zardaverine

Indexed keywords

5 (4 ACETAMIDOPHENYL) 2(1H) PYRAZINONE; ACETYLCHOLINE; CYCLIC GMP; HISTAMINE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SPASMOLYTIC AGENT; THEOPHYLLINE; ZAPRINAST; ZARDAVERINE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GUINEA PIG; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE TONE; TRACHEA MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ACETYLCHOLINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; GUINEA PIGS; HISTAMINE; ISOENZYMES; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NITROPRUSSIDE; PARASYMPATHOLYTICS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRAZINES; TRACHEA;

EID: 0032882385     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702779     Document Type: Article

References (49)

1. BARNES, P.J. (1998). Chronic obstructive pulmonary disease: new opportunities for drug development. Trends. Pharmacol. Sci., 19, 415-423.
2. BEAVO, J. (1987), Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv. Second Messenger. Phosphoprotein. Res., 22, 1-38.
3. BEAVO, J. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 75, 725-748.
4. BEAVO, J., CONTI, M. & HEASIIP, R.J. (1994). Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol., 46, 399-405.
5. 3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle. Br. J. Pharmacol., 124, 47-54.
6. CONTI, M., NEMOZ, G., SETTE, C. & VINCINI, E. (1995), Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocrine. Rev., 16, 370-389.
7. DEGERMAN, E., BELFRAGE, P. & MANGANIELLO, V.C. (1997). Structure, localization, and regulation or cGMP-inhibited phosphodiesterase (PDE3). J. Biol. Chem., 272, 6823-6826.
8. DENT, G. & GIEMBYCZ, M.A. (1995). Selective phosphodiesterase inhibitors in the therapy of asthma. Clin. Immunother., 3, 423-437.
9. FISHER, D.A., SMITH, J.F., PILIAR, J.S., ST. DENIS, S.H. & CHENG, J.B. (1998a). Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem. Biophys. Res. Commun., 246, 570-577.
10. FISHER, D.A., SMITH, J.F., PILLAR, J.S., ST. DENIS, S.H. & CHENG, J.B. (1998b). Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem., 273, 15559-15564.
11. FUJISHIGE, K,. KOTERA, J., MICHIBATA, H., YUASA, K., TAKE-BAYASHI, S.I., OKUMURA. K. & OMORI, K. (1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP. J. Biol. Chem., 274, 18438-18445.
12. GIEMBYCZ, M.A. (1992). Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of asthama? Biochem. Pharmacol., 43, 2041-2051.
13. GIEMBYCZ, M.A. & BARNES, P.J. (1991). Selective inhibition of a high affinity type IV cyclic AMP phosphodiesterase in bovine trachealis by AH 21-132. Relevance to the spasmolytic and anti-spasmogenic actions or AH 21-132 in the intact tissue. Biochem. Pharmacol., 42, 663-677.
14. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol., 118, 1945-1958.
15. GIEMBYCZ, M.A., DENT, G. & SOUNESS, J.E. (1997). Theophylline and isoenzyme-selective phosphodiesterase inhibitors. In: Kay, A.B. (ed.). Allergy & Allergic Diseases. Blackwell Scientific: London. pp 531-567.
16. GIEMBYCZ, M.A. & KELLY, J.J. (1994). Current status of cyclic nucleotide phosphodiesterase isoenzymes. In: Piper, P.J. & Costello, J. (eds). Methylxanthines and Phosphodiesterase, Inhibitors and the Treatment of Respiratory Disease. Parthenon Publishing: London. pp 27-80.
17. GIEMBYCZ, M.A. & RAEBURN, D. (1991). Putative substrates for cyclic nucleotide-dependent protein kinases and the control of airway smooth muscle tone. J. Auton. Pharmacol., 11, 365-398.
18. GIEMBYCZ, M.A. & SOUNESS, J.E. (1996). Phosphodiesterase 4 inhibitors as potential therapeutic agents in allergic disease. In: Townley, R.G. & Agarwal, D.K. (eds). Immunopharmacology of Allergic Disease. Marcel-Dekker: New York. pp 523-559.
19. HAGIWARA, M., ENDO, T. & HIDAKA, H. (1984). Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol., 33, 453-457.
20. HANIFIN, J.M., CHAN, S.C., CHENG, J.B., TOFTE, S.J., HENDERSON, W.R., KIRBY, O.S. & WEINER, E.S. (1996). Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol., 107, 151-156.
21. HARRIS, A.L., CONNELL, M.J., FERGUSON, E.W., WALLACE, A.M., GORDON, R.J., PAGANI, E.D. & SILVER, P.J. (1989). Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J. Pharmacol. Esp. Ther., 251, 199-206.
22. HATZELAMANN, A., ENGELSTATTER, R., MORLEY, J. & MAZZONI, L. (1996). Enzymatic and functional aspects of dual-selective PDE3 4 inhibitors. In: Schudt, C., Dent, G. & Rabe, K.F. (eds). Phosphodiesterase Inhibitors. Academic Press: London, pp 147-160.
23. HOUSLAY, M.D. & MILLIGAN, G. (1997). Tailoring cAMP-signalling responses through isoform multiplicity. Trends. Biochem. Sci., 22, 217-224.
24. LOUGHNEY, K. & FERGUSON, K (1994). The human cyclic nucleotide phosphodiesterases. In: Piper, P.J. & Costello, J. (eds). Methylxanthines and Phosphodiesterase Inhibitors and the Treatment of Respiratory Disease. Parthenon Publishing: London. pp 81-100.
25. LOUGHNEY, K. & FERGUSON, K. (1996). Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods. In: Schudt, C., Dent, G. & Rabe, K.F. (eds). Phosphodiesterase Inhibitors. Academic Press: London, pp 1-19.
26. LOUGHNEY, K., SNYDER, P.B., UHER, L., ROSMAN, G.J., FERGUSON, K. & FLORIO, V.A. (1999). Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene., 234, 109-117.
27. MAURICE, D.H. & HASLAM, R.J. (1990). Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur. J. Pharmacol., 191, 471-475.
28. MIYAMOTO, K., KURITA, M., SAKAI, R., SANAE, F., WAKUSAWA, S. & TAKAGI, K. (1994). Cyclic nucleotide phosphodiesterase isoenzymes in guinea-pig tracheal muscle and bronchorelaxation by alkylxanthines. Biochem. Pharmacol., 48, 1219-1223.
29. MURRAY, K.J., EDEN, R.J., DOLAN, J.S., GRIMSDITCH, D.C., STUTCHBURY, C.A., PATEL, B., KNOWLES, A., WORBY, A., LYNHAM. J.A. & COATES. W.J. (1992). The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function. Br. J. Pharmacol., 107, 463-470.
30. NICHOLSON, C.D., CHALLISS, R.A.J. & SHAHID, M. (1991). Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends. Pharmacol. Sci., 12, 19-27.
31. PALMER, D., TSOI, K. & MAURICE, D.H. (1998). Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ. Res., 82, 852-861.
32. PODZUWFIT, T., NENNSTIEL, P. & MULLER, A. (1995). Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal., 7, 733-738.
33. ROGERS, D.F. & GIEMBYCZ, M.A. (1998). Conquering airway inflammation in the 21st century. Drug Discovery Today., 3, 532-535.
34. SCHUDT, C., WINDER, S., MULLER, B. & UKENA, D. (1991). Zardaverine as a selective inhibitor of phosphodiesterase isoenzymes. Biochem. Pharmacol., 42, 153-162.
35. SODERLING, S.H., BAYUGA, S.J. & BEAVO, J.A. (1998). Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem., 273, 15553-15558.
36. SODERLING, S.H., BAYUGA, S.J. & BEAVO, J.A. (1999). Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. U.S.A., 96, 7071-7076.
37. SOUNESS, J.E. & FOSTER, M. (1998). Potential of phosphodiesterase type 4 inhibitors in the treatment of rheumatoid arthritis. Curr. Res. Rheum. Arthr., 2, 255-268.
38. SOUNESS, J.E. & GIEMBYCZ, M.A. (1994). Cyclic nucleotide phosphodiesterases in airways smooth muscle. In: Raeburn, D. & Giembycz, M.A. (eds). Airways Smooth Muscle: Biochemical Control of Contraction and Relaxation. Birkhauser Verlag: Basel, pp 273-308.
39. TORPHY T.J. (1998). Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care. Med., 157, 351-370.
40. TORPHY, T.J. & CIESLINSKI, L.B. (1990). Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol. Pharmacol., 37, 206-214.
41. TORPHY, T.J., MURRAY, K.J. & ARCH, J.R.S. (1994). Selective phosphodiesterase isoenzyme inhibitors. In: Page, C.P. & Metzger, W.J. (eds). D rugs and the Lung. Raven Press: New York, pp 397-477.
42. TORPHY, T.J. & UNDEM, B.J. (1991). Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax., 46, 512-523.
43. TORPHY, T.J., UNDEM, B.J., CIESLINSKI, L.B., LUTTMANN, M.A., REEVES, M.L. & HAY, D.W.P. (1993). Identification, characterization and functional role of phosphodiesterase isoenzymes in human airway smooth muscle. J. Pharmacol. Exp. Ther., 265, 1213-1223.
44. TORPHY, T.J., ZHENG, C., PETERSON, S.M., FISCUS, R.R., RINARD, G.A. & MAYER, S.E. (1985). Inhibitory effect of methacholine on drug-induced relaxation, cyclic AMP accumulation, and cyclic AMP-dependent protein kinase activation in canine tracheal smooth muscle. J. Pharmacol. Exp. Ther., 233, 409-417.
45. TURNER, N.C., LAMB, J., WORBY, A. & MURRAY, K.J. (1994). Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside. Br. J. Pharmacol., 111, 1047-1052.
46. UNDERWOOD, D.C., KOTZER, C.J., BOCHNOWICZ, S., OSBORN, R.R., LUTTMANN, M.A., HAY, D.W.P. & TORPHY, T.J. (1994). Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary cosinophil influx in guinea pigs. J. Pharmacol. Exp. Ther., 270, 250-259.
47. VAN AMSTERDAM, R.G.M., MEURS, H., BROUWER, F., POSTEMA, J.B., TIMMERMANS, A. & ZAAGSMA, J. (1989). Role of phosphoinositide metabolism in functional antagonism of airway smooth muscle contraction by β-adrenoceptor agonists. Eur. J. Pharmacol., 172, 175-183.
48. VAN ROSSUM, J.M. (1963). Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. Ther., 143, 299-330.
49. ZHOU, H.L. & TORPHY, T.J. (1991). Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators. J. Pharmacol. Exp. Ther., 258, 972-978.